Transformational cell therapies for patients with pancreatic disease

David Blanford

David E. Blanford, CPA

Chief Operating Officer (Koligo Therapeutics Inc.)

David Blanford provides a wealth of financial experience ranging from operational and financial process integration to acquisitions and complex financing. His industry experience is in pharmaceutical research and development and manufacturing. David has served as an executive and a board of director for multiple private companies.

David was introduced to Koligo and the other co-founders from the University of Louisville in mid-2016, and assisted Matthew and the other co-founders with financial modeling and accounting relating to the introduction of commercial operations in 2017, and initial capital raise in early 2018.

Previously, David served as Chief Financial Officer of The Geneva Foundation where he provided focused leadership to utilize limited capital resources to achieve the long-term strategic objectives of the Organization while increasing overall financial health. As CFO of Connecticut Electric & Switch Mfg. Co, David managed rapid growth, both organically and via acquisition, while expanding manufacturing capabilities in China and Mexico, leading ultimately to a successful divestiture. Following divestiture to a private-equity firm, David continued serving as CFO for the company until he transferred to another portfolio company in Kentucky.

David is a graduate of Oral Roberts University with a BS in Accounting, and is a Certified Public Accountant. Outside of the office, he enjoys spending time with family, reading, and baseball.

Kyslecel personalized cell therapy for chronic pancreatitis. Because pain should not define your life.